Vaxxinity Long Term Debt

The latest long-term debt for VAXX is $13M as of December 2023. That compares with $13M in the prior-year period — up 1.7% year over year. Investors often review this figure alongside Vaxxinity's historical trend and sector peers before judging valuation or financial health.

Over the past year, VAXX's long-term debt moved from $13M to $13M — a 1.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vaxxinity's operating scale or balance-sheet position.

A long-term debt figure of $13M for VAXX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VAXX's long-term debt ($13M), review year-over-year change from $13M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.